Skip to main content
Tech.euFundingExplorerBeta

Diurnal

Exited

Diurnal is an innovative UK-based specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions

Diurnal is tracked in the Tech.eu funding database. Based in Cardiff, UK; active in Healthtech. Acquired by Neurocrine in 2022. Data as of Nov 2026.

Total raised
—
no tracked rounds
Funding rounds
0
Investors
0
distinct backers
Active since
—

Funding rounds

0 rounds
No funding rounds recorded.

Exit

Type
acquisition
Date
Aug 2022
Value
€56M
Acquiror
Neurocrine (United States of America)

Related news

Similar companies

same sector, similar size

Global coverage: FundingData